| Literature DB >> 21549323 |
Jan Helge Solbakk1, Laurie Zoloth.
Abstract
Who should go first in phase-I human trials when neither risks nor benefits can be estimated? By assessing concerns raised by Bretzner et al. (2011), we highlight a tragic dimension underlying all such trials. We discuss strategies to avoid the pitfalls of ethical hubris by promoting fidelity and trust.Entities:
Mesh：
Year: 2011 PMID： 21549323 DOI： 10.1016/j.stem.2011.04.009
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633